AdultPediatricDosage Forms & Strengths injectable solution (single-dose vials) 10mg/mL (10mL, 50mL vials) Biosimilars to Rituxan Riabni (rituximab-arrx) Ruxience (rituximab-rituximab-pvvr) Truxima (rituximab-abbs) Non-Hodgkin Lymphoma Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL Indicated for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent 375 mg/m2 IV once weekly x 4-8 doses Retreatment: 375 mg/m2 IV once weekly x 4 doses In combination with ibritumomab Day 1: Rituximab 250 mg/m2 IV Day 7, 8, or 9: Rituximab 250 mg/m2 IV; administer ibritumomab within 4 hr following completion of rituximab infusion Refer to ibritumomab tiuxetan for full prescribing information regarding regimen Previously untreated follicular, CD20-positive, B-cell NHL Indicated in previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab product in combination with chemotherapy, as single-agent maintenance therapy 375 mg/m2 IV on Day 1 of each chemotherapy cycle for up to 8 doses Maintenance therapy following 8 weeks after completion of combination chemotherapy in patients with complete or partial response: Initiate as a single-agent q8weeks x 12 doses In combination with ibritumomab Day 1: Rituximab 250 mg/m2 IV Day 7, 8, or 9: Rituximab 250 mg/m2 IV; administer ibritumomab within 4 hr following completion of rituximab infusion Refer to ibritumomab tiuxetan for full prescribing information regarding regimen Nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL Indicated for treatment in patients with nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Following completion of 6-8 cycles of CVP chemotherapy, 375 mg/m2 IV once weekly x 4 doses at 6-month intervals for up to 16 doses Previously untreated diffuse large B-cell, CD20-positive NHL Indicated for treatment in patients with previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens 375 mg/m2 IV on Day 1 of each cycle of chemotherapy for up to 8 infusions Chronic Lymphocytic Leukemia Indicated for untreated and previously treated CD20-positive CLL; combined therapy with fludarabine and cyclophosphamide (FC) 375 mg/m2 IV infusion on Day 1 of 1st cycle (for 1st cycle, administer 1 day before chemotherapy with FC), THEN 500 mg/m2 IV on Day 1 of cycles 2-6 (administer on same day as chemotherapy with FC) Fludarabine & cyclophosphamide dosage Fludarabine: 25 mg/m2 IV qDay x 3 days Cyclophosphamide: 250 mg/m2 IV qDay x 3 days Repeat q28 days x 6 cycles Rheumatoid Arthritis Indicated, in combination with methotrexate, for treatment of moderately-to severely-active rheumatoid arthritis (RA) who have had an inadequate response to ≥1 tumor necrosis factor (TNF) antagonist therapies 1000 mg IV infusion, repeat after 2 week (2 infusions separated by 2 week is 1 course) Repeat course q24weeks or based on clinical evaluation (but no sooner than 16 weeks) Not to exceed 1000 mg/dose Wegener Granulomatosis Indicated for adults with granulomatosis with polyangiitis (GPA; Wegener granulomatosis) in combination with glucocorticoids Induction: 375 mg/m2 IV qWeek x 4 weeks Follow up treatment If disease control achieved with induction treatment, initiate follow up treatment Induction treatment with rituximab: Initiate follow up treatment within 24 weeks after last rituximab induction dose or based on clinical evaluation, but no sooner than 16 weeks after last induction dose Induction treatment with other standard of care immunosuppressants: Initiate follow up treatment within 4 weeks following achievement of disease control 500 mg IV on Days 1 and 15, THEN q6months thereafter based on clinical evaluation Glucocorticoid regimen Also see premedication Induction Methylprednisolone 1000 mg IV qDay x 1-3 days followed by prednisone PO 1 mg/kg/day (not to exceed 80 mg/day and tapered per clinical need) are recommended to treat severe vasculitis symptoms Begin within 14 days before or with initiation of rituximab and may continue during and after the 4 week induction course Follow up treatment Methylprednisolone 100 mg IV to be completed 30 minutes before each rituximab IV infusion Microscopic Polyangiitis Indicated for adults with microscopic polyangiitis (MPA) in combination with glucocorticoids Induction: 375 mg/m2 IV qWeek x 4 weeks Follow up treatment If disease control achieved with induction treatment, initiate follow up treatment Induction treatment with rituximab: Initiate follow up treatment within 24 weeks after last rituximab induction dose or based on clinical evaluation, but no sooner than 16 weeks after last induction dose Induction treatment with other standard of care immunosuppressants: Initiate follow up treatment within 4 weeks following achievement of disease control 500 mg IV on Days 1 and 15, THEN q6months thereafter based on clinical evaluation Glucocorticoid regimen Also see premedication Induction Methylprednisolone 1000 mg IV qDay x 1 to 3 days followed by prednisone PO 1 mg/kg/day (not to exceed 80 mg/day and tapered per clinical need) are recommended to treat severe vasculitis symptoms Begin within 14 days before or with initiation of rituximab and may continue during and after the 4 week induction course Follow up treatment Methylprednisolone 100 mg IV to be completed 30 minutes before each rituximab IV infusion Pemphigus Vulgaris Rituxan only Indicated for adults with moderate-to-severe pemphigus vulgaris (PV) Initial: 1000 mg IV once, then repeat dose in 2 weeks (ie, two 1000-mg doses 2 weeks apart); use in combination with a tapering course of glucocorticoids Maintenance: 500 mg IV at Month 12 and q6Months thereafter or based on clinical evaluation Treatment relapse: 1000 mg IV and consider resuming or increasing the glucocorticoid dose based on clinical evaluation Orphan Designations Treatment of immune thrombocytopenic purpura (ITP) Sponsor Genentech, Inc; 1 DNA Way; South San Francisco, CA 94080-4990 Rasmussen Encephalitis (Orphan) Orphan designation for treatment of Rasmussen encephalitis Sponsor Keck Graduate Institute of Applied Life Sciences; 535 Watson Drive; Claremont, California 91711 Dosage Forms & Strengths injectable solution (single-dose vials) 10mg/mL (10mL, 50mL vials) Granulomatosis with Polyangiitis and Microscopic Polyangiitis Rituxan only Indicated in combination with glucocorticoids for children aged ≥2 years with granulomatosis with polyangiitis (GPA) (Wegener granulomatosis) and for microscopic polyangiitis (MPA) Induction: 375 mg/m2 IV qWeek for 4 weeks Before first infusion, administer methylprednisolone 30 mg/kg IV (not to exceed 1g/day) qDay for 3 days Following methylprednisolone IV, continue oral corticosteroids per clinical practice Follow up treatment of patients who achieve disease control with induction treatment 250 mg/m2 IV x2 doses separated by 2 weeks, THEN 250 mg/m2 IV q6months thereafter based on clinical evaluation If induction treatment of active disease was with a rituximab product, initiate follow up treatment with rituximab within 24 weeks, but no sooner than 16 weeks after last induction infusion based on clinical evaluation If induction treatment of active disease was with other standard of care immunosuppressants, initiate rituximab follow up treatment within the 4 week period following achievement of disease control Non-Hodgkin Lymphoma Rituxan only Indicated in combination with chemotherapy for previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL) in pediatric patients aged ≥6 months Given in combination with systemic Lymphome Malin B (LMB) chemotherapy Premedicate with acetaminophen and diphenhydramine (or equivalent) 30-60 minutes before each rituximab infusion Prephase: No rituximab given Induction courses 1 and 2 2 rituximab infusions during each induction courses, COPDAM1 and COPDAM2 COPDAM: Cyclophosphamide, vincristine, prednisolone, doxorubicin, methotrexate Day -2: 375 mg/m2 IV for each course (1st and 3rd infusion); during the 1st induction course, prednisone is part of the chemotherapy course and should be administer before administration Day 1: 375 mg/m2 IV for each course (2nd and 4th infusions); administer 48 hr after the first rituximab infusion Consolidation courses 1 and 2 1 rituximab infusion during each of 2 consolidation courses of CYM/CYVE CYM: Cytarabine, methotrexate CYVE: Cytarabine, etoposide Day 1: 375 mg/m2 IV for each course (5th and 6th infusion) Rheumatoid Arthritis Not studied in pediatric patients with polyarticular juvenile idiopathic arthritis (PJIA) due to concerns regarding the potential for prolonged immunosuppression as a result of B-cell depletion in the developing juvenile immune systemInteraction CheckerEnter a drug name and rituximabNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (22)adenovirus types 4 and 7 live, oralrituximab, adenovirus types 4 and 7 live, oral. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.axicabtagene ciloleucelrituximab, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.axicabtagene ciloleucel, rituximab. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.baricitinibbaricitinib, rituximab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.brexucabtagene autoleucelrituximab, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.brexucabtagene autoleucel, rituximab. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.certolizumab pegolrituximab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.ciltacabtagene autoleucelrituximab, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ciltacabtagene autoleucel, rituximab. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.idecabtagene vicleucelrituximab, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.idecabtagene vicleucel, rituximab. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.influenza virus vaccine quadrivalent, intranasalrituximab, influenza virus vaccine quadrivalent, intranasal. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.lisocabtagene maraleucelrituximab, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.lisocabtagene maraleucel, rituximab. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.measles (rubeola) vaccinerituximab, measles (rubeola) vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.measles mumps and rubella vaccine, liverituximab, measles mumps and rubella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.measles, mumps, rubella and varicella vaccine, liverituximab, measles, mumps, rubella and varicella vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.paliferminpalifermin increases toxicity of rituximab by Other (see comment). Avoid or Use Alternate Drug. Comment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis.ropeginterferon alfa 2bropeginterferon alfa 2b, rituximab. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.rotavirus oral vaccine, liverituximab, rotavirus oral vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.rubella vaccinerituximab, rubella vaccine. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.smallpox (vaccinia) vaccine, liverituximab, smallpox (vaccinia) vaccine, live. immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Safety of immunization with live viral vaccines following rituximab therapy has not been studied and vaccination with live virus vaccines is not recommended.tisagenlecleucelrituximab, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.tisagenlecleucel, rituximab. Either increases effects of